Buscar
Drugs Made In America Acquisition II Ord Shs
DMIIAñadir a la lista de seguimiento
10.010USD
-0.010-0.10%
Cierre 05/08, 16:00（ET）Cotizaciones retrasadas 15 min
637.64MCap. mercado
31.77P/E TTM
Más Datos de Drugs Made In America Acquisition II Ord Shs Compañía
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.
Información de Drugs Made In America Acquisition II Ord Shs
Símbolo de cotizaciónDMII
Nombre de la empresaDrugs Made In America Acquisition II Corp
Fecha de salida a bolsaSep 25, 2025
Director ejecutivoStockwell (Lynn)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscal- -
Dirección1 East Broward Boulevard
CiudadFT LAUDERDALE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33301
Teléfono19548703099
Sitio Web
Símbolo de cotizaciónDMII
Fecha de salida a bolsaSep 25, 2025
Director ejecutivoStockwell (Lynn)
Ejecutivos de Drugs Made In America Acquisition II Ord Shs
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 19 de feb
Actualizado: jue., 19 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Drugs Made In America Acquisition II LLC
4.64%
Magnetar Capital Partners LP
4.24%
Glazer Capital, LLC
3.69%
First Trust Capital Management L.P.
3.25%
Conaway (Charles C.)
3.14%
Otro
81.04%
Accionistas
Accionistas
Proporción
Drugs Made In America Acquisition II LLC
4.64%
Magnetar Capital Partners LP
4.24%
Glazer Capital, LLC
3.69%
First Trust Capital Management L.P.
3.25%
Conaway (Charles C.)
3.14%
Otro
81.04%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
29.83%
Investment Advisor/Hedge Fund
16.78%
Investment Advisor
8.57%
Individual Investor
8.48%
Corporation
6.74%
Pension Fund
2.12%
Research Firm
1.24%
Bank and Trust
0.20%
Otro
26.04%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q4
1
666.67K
0.00%
--
2026Q1
58
37.42M
58.75%
+33.66M
2025Q4
7
3.04M
4.64%
+3.04M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Drugs Made In America Acquisition II LLC
4.83M
7.37%
+4.83M
--
Dec 03, 2025
Magnetar Capital Partners LP
2.70M
4.12%
+2.70M
--
Dec 31, 2025
Glazer Capital, LLC
2.35M
3.58%
+2.35M
--
Dec 31, 2025
First Trust Capital Management L.P.
2.07M
3.15%
+2.07M
--
Dec 31, 2025
Conaway (Charles C.)
2.00M
3.05%
+2.00M
--
Dec 03, 2025
Hudson Bay Capital Management LP
1.97M
3%
+1.97M
--
Dec 31, 2025
Wolverine Asset Management, LLC
1.06M
1.62%
+1.06M
--
Dec 31, 2025
Tenor Capital Management Co., L.P.
1.50M
2.29%
+1.50M
--
Dec 31, 2025
Polar Asset Management Partners Inc.
1.50M
2.29%
+1.50M
--
Dec 31, 2025
Millennium Management LLC
1.50M
2.29%
+1.50M
--
Dec 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
